Precision Medicine for Indolent Systemic Mastocytosis (PRISM)

This study is being done to better understand how symptoms of Systemic Mastocytosis (SM) relate to biological signals and to better understand how different treatments affect these signals.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Systemic Mastocytosis Immune System Diseases Mast Cell Activation Disorders Mastocytosis Mastocytosis, Systemic Neoplasms Neoplasms by Histologic Type Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic

Rochester, Minnesota, 55905, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of indolent systemic mastocytosis as defined by the World Health Organization 2022 criteria.
Doses of baseline treatment medications are stable for ≥ 14 days prior to enrollment.
Patient must have an Eastern Cooperative Oncology Group Performance Status of 0 to 2.

Exclusion criteria

Diagnosis of advanced systemic mastocytosis defined by established criteria as outlined by the World Health Organization 2022 criteria.
Patient must not have had any cytoreductive therapy including but not limited to cladribine, interferon alpha, pegylated interferon, or antibody therapy < 28 days prior to enrollment.
Any other significant medical issue as determined by the principal investigator.

Treatment and study plan

Primary outcomes

Participant Completion Rate at 12 Weeks

Time frame: 12 weeks

Proportion of enrolled participants who remain in the study and complete the 12 weeks of sample and data collection.

Study contacts

Contact information is provided by the study sponsor or research team.

Kay Bachman

CONTACT

[email protected]

507-284-5689

Laurie Mulhern

CONTACT

[email protected]

507-284-8160

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Acronym: PRISM

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Aug 11, 2026
Registry last updated: Aug 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed